Value Dossier Icon

Challenges and Chances of the EU-HTA

The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of the Joint Clinical Assessments on the level of the European Union (EU) starting in 2025. Until then, the necessary health technology assessment (HTA) process needs to be defined and refined. Today, we were honored to present our

2022-04-05T15:02:46+02:0023. February 2022|European HTA|0 Comments
Go to Top